BMO Capital Markets Issues Pessimistic Forecast for Teladoc Health (NYSE:TDOC) Stock Price

Teladoc Health (NYSE:TDOC) had its price target lowered by stock analysts at BMO Capital Markets from $8.00 to $5.00 in a note issued to investors on Thursday,Benzinga reports. The firm currently has a “market perform” rating on the health services provider’s stock. BMO Capital Markets’ target price would indicate a potential downside of 5.93% from the stock’s previous close.

Several other research analysts have also recently weighed in on TDOC. TD Cowen decreased their price objective on shares of Teladoc Health from $8.00 to $6.00 and set a “hold” rating on the stock in a research report on Thursday. Stifel Nicolaus cut their price target on shares of Teladoc Health from $8.00 to $6.00 and set a “hold” rating for the company in a research note on Thursday. Piper Sandler reissued an “overweight” rating and issued a $9.00 price target (down from $12.00) on shares of Teladoc Health in a report on Thursday. Wells Fargo & Company dropped their price objective on shares of Teladoc Health from $8.00 to $6.00 and set an “equal weight” rating for the company in a report on Thursday. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Teladoc Health in a research report on Monday, December 29th. Four equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Teladoc Health presently has a consensus rating of “Hold” and a consensus price target of $8.11.

Teladoc Health Price Performance

Teladoc Health stock traded up $0.67 during midday trading on Thursday, reaching $5.32. 14,644,582 shares of the stock were exchanged, compared to its average volume of 6,787,662. Teladoc Health has a 52 week low of $4.40 and a 52 week high of $10.02. The company has a debt-to-equity ratio of 0.71, a quick ratio of 2.60 and a current ratio of 2.70. The firm has a market cap of $943.25 million, a PE ratio of -4.15 and a beta of 2.12. The company’s fifty day moving average is $6.06 and its 200-day moving average is $7.22.

Teladoc Health (NYSE:TDOC) last released its quarterly earnings results on Wednesday, February 25th. The health services provider reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.05. Teladoc Health had a negative net margin of 8.84% and a negative return on equity of 10.59%. The firm had revenue of $642.27 million during the quarter, compared to analyst estimates of $635.33 million. During the same period in the previous year, the business earned ($0.28) EPS. The business’s revenue for the quarter was up .3% on a year-over-year basis. Teladoc Health has set its Q1 2026 guidance at -0.450–0.350 EPS and its FY 2026 guidance at -1.100–0.700 EPS. On average, sell-side analysts forecast that Teladoc Health will post -1.16 EPS for the current year.

Insider Buying and Selling at Teladoc Health

In other Teladoc Health news, insider Fernando M. Rodrigues sold 4,209 shares of the business’s stock in a transaction on Wednesday, December 3rd. The shares were sold at an average price of $7.48, for a total value of $31,483.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Charles Divita III sold 17,138 shares of the company’s stock in a transaction dated Thursday, December 11th. The shares were sold at an average price of $7.63, for a total transaction of $130,762.94. Following the sale, the chief executive officer owned 201,036 shares of the company’s stock, valued at approximately $1,533,904.68. The trade was a 7.86% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 33,288 shares of company stock worth $251,684 in the last 90 days. 0.58% of the stock is owned by company insiders.

Hedge Funds Weigh In On Teladoc Health

A number of large investors have recently bought and sold shares of the stock. Allianz Asset Management GmbH boosted its stake in shares of Teladoc Health by 189.2% during the 3rd quarter. Allianz Asset Management GmbH now owns 1,619,391 shares of the health services provider’s stock valued at $12,518,000 after purchasing an additional 1,059,458 shares in the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in Teladoc Health in the second quarter worth about $2,722,000. Jupiter Asset Management Ltd. bought a new stake in Teladoc Health during the 3rd quarter valued at approximately $7,576,000. Banco Bilbao Vizcaya Argentaria S.A. grew its holdings in shares of Teladoc Health by 23.1% during the 2nd quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 212,933 shares of the health services provider’s stock worth $1,841,000 after acquiring an additional 39,956 shares during the period. Finally, Empowered Funds LLC bought a new position in shares of Teladoc Health in the 2nd quarter worth approximately $5,040,000. 76.82% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Teladoc Health

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Q4 results beat expectations — Teladoc reported revenue of $642.3M (above $635.3M consensus) and EPS of ($0.14), topping estimates. The beat reduces near‑term earnings uncertainty and provides proof of stabilization after prior losses. Q4 sales surprise
• Positive Sentiment: Conference call highlighted growth in Integrated Care and strategic repositioning of BetterHelp — management emphasized areas of improving unit economics and product focus that could drive margin recovery over time. Investors often reward visible operational progress even when near‑term guidance is cautious. Earnings call highlights
• Neutral Sentiment: Deeper metric readouts available — analysts and outlets (e.g., Zacks) are parsing subscriber, utilization and margin metrics to assess sustainability of the beat; these details will influence revisions to models but don’t yet change the headline picture. Zacks analysis
• Negative Sentiment: Forward guidance disappointed — Q1 2026 EPS guidance of -0.450 to -0.350 and FY 2026 EPS of -1.100 to -0.700 both sit below consensus; Q1 revenue guidance ($598M–$620M) is also below Street estimates. This increases near‑term downside risk and keeps profitability recovery uncertain. Guidance details
• Negative Sentiment: Analysts cut price targets — Wells Fargo and Stifel reduced targets from $8 to $6 and kept neutral/hold stances, signaling tempered expectations for upside and contributing to mixed sell‑side sentiment. Benzinga

About Teladoc Health

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.